NFL Biosciences SA (EPA:ALNFL)
France · Delayed Price · Currency is EUR 1.334
-0.006 (-0.45%)
Jan 9, 2026, 5:29 PM CET
NFL Biosciences Company Description
NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France.
The company’s pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage.
It has scientific collaboration with McLean Hospital to deepen the understanding of the mechanism of action of NFL-101, its proprietary botanical drug candidate for smoking cessation.
NFL Biosciences SA was incorporated in 2006 and is headquartered in Castelnau-le-Lez, France.
NFL Biosciences SA
| Country | France |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Bruno Lafont |
Contact Details
Address: 199 Rue HElEne Boucher Castelnau-le-Lez, 34170 France | |
| Phone | 33 4 11 93 76 67 |
| Website | nflbiosciences.com |
Stock Details
| Ticker Symbol | ALNFL |
| Exchange | Euronext Paris |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FR0014003XT0 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Bruno Lafont M.B.A., M.Sc. | Founder, Chief Executive Officer, MD and Chairman |
| Guillaume Audema | Chief Financial Officer |
| Dr. Ignacio Faus M.B.A., Ph.D. | Deputy Managing Director and Director |
| Dr. Yannick Pletan M.D., M.Sc. | Chief Medical Officer and Director |
| Lara Babich | Head of Development and Manufacturing |